PDL BioPharma Stock Price, News & Analysis (NASDAQ:PDLI)

$2.84 -0.01 (-0.35 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$2.84
Today's Range$2.86 - $2.78
52-Week Range$1.93 - $3.55
Volume988,229 shs
Average Volume1.85 million shs
Market Capitalization$439.87 million
P/E Ratio5.88
Dividend YieldN/A
Beta0.46

About PDL BioPharma (NASDAQ:PDLI)

PDL BioPharma logoPDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:PDLI
  • CUSIP: 69329Y10
  • Web: www.pdl.com
Debt:
  • Debt-to-Equity Ratio: 0.14%
  • Current Ratio: 1.94%
  • Quick Ratio: 1.90%
Price-To-Earnings:
  • Trailing P/E Ratio: 5.88
  • Forward P/E Ratio: 4.24
Sales & Book Value:
  • Annual Sales: $244.3 million
  • Price / Sales: 1.79
  • Cash Flow: $0.42 per share
  • Price / Cash: 6.81
  • Book Value: $4.56 per share
  • Price / Book: 0.62
Profitability:
  • Trailing EPS: $0.50
  • Net Income: $63.6 million
  • Net Margins: 24.51%
  • Return on Equity: 9.33%
  • Return on Assets: 5.81%
Misc:
  • Employees: 11
  • Outstanding Shares: 154,340,000
 

Frequently Asked Questions for PDL BioPharma (NASDAQ:PDLI)

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How will PDL BioPharma's stock buyback program work?

PDL BioPharma declared that its board has initiated a stock buyback plan on Monday, September 25th 2017, which allows the company to buyback $25,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board believes its shares are undervalued.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma, Inc. (NASDAQ:PDLI) issued its quarterly earnings data on Thursday, November, 2nd. The biotechnology company reported $0.14 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.13 by $0.01. The biotechnology company had revenue of $62.75 million for the quarter, compared to analyst estimates of $61.86 million. PDL BioPharma had a net margin of 24.51% and a return on equity of 9.33%. The firm's revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.08 EPS. View PDL BioPharma's Earnings History.

Where is PDL BioPharma's stock going? Where will PDL BioPharma's stock price be in 2017?

2 brokerages have issued 1 year price targets for PDL BioPharma's stock. Their forecasts range from $3.00 to $4.00. On average, they expect PDL BioPharma's share price to reach $3.50 in the next twelve months. View Analyst Ratings for PDL BioPharma.

What are Wall Street analysts saying about PDL BioPharma stock?

Here are some recent quotes from research analysts about PDL BioPharma stock:

  • 1. According to Zacks Investment Research, "PDL BioPharma’s earnings in the second quarter of 2017 surpassed estimates. The company is focused on acquiring and managing income-generating assets. PDL BioPharma has royalty agreements with several companies, whereby it has royalty rights on product sales. We are positive on the company’s recent strategic shift, wherein, it is making equity investments in product-focused companies. The company’s royalty agreement with oncology-focused company, ARIAD, is also encouraging. PDL BioPharma’s shares have outperformed the industry in a year. However, the company is heavily dependent on its partners for royalty revenues, which is hardly a risk-free strategy. We are also concerned about PDL BioPharma’s revenue stream in the futureas its growth prospects rely on the timing and ability to acquire new income-generating assets in order to provide recurring revenues." (8/16/2017)
  • 2. Cowen and Company analysts commented, "PDL reported an in-line Q1 with both total revenue ($45MM vs $43MM) and EPS." (5/3/2017)

Who are some of PDL BioPharma's key competitors?

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the folowing people:

  • Dominique Monnet, President (Age 59)
  • John Peter McLaughlin, Chief Executive Officer, Director (Age 65)
  • Peter S. Garcia, Chief Financial Officer, Vice President (Age 55)
  • Steffen Pietzke CPA, Chief Accounting Officer, Vice President - Finance (Age 44)
  • Christopher Lewis Stone J.D., Vice President, General Counsel, Secretary (Age 52)
  • Harold E. Selick Ph.D., Lead Independent Director (Age 62)
  • Paul R. Edick, Independent Director (Age 62)
  • David W. Gryska, Independent Director (Age 61)
  • Jody S. Lindell, Independent Director (Age 65)
  • Samuel R. Saks M.D., Independent Director (Age 62)

Who owns PDL BioPharma stock?

PDL BioPharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (5.65%), Mackenzie Financial Corp (3.29%), Schwab Charles Investment Management Inc. (2.06%), Skandinaviska Enskilda Banken AB publ (0.82%), Prudential Financial Inc. (0.81%) and Seizert Capital Partners LLC (0.75%). Company insiders that own PDL BioPharma stock include Peter S Garcia and Steffen Pietzke. View Institutional Ownership Trends for PDL BioPharma.

Who sold PDL BioPharma stock? Who is selling PDL BioPharma stock?

PDL BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, JPMorgan Chase & Co., Systematic Financial Management LP, Seizert Capital Partners LLC, Strs Ohio, Advisors Asset Management Inc., California State Teachers Retirement System and Eqis Capital Management Inc.. View Insider Buying and Selling for PDL BioPharma.

Who bought PDL BioPharma stock? Who is buying PDL BioPharma stock?

PDL BioPharma's stock was acquired by a variety of institutional investors in the last quarter, including Mackenzie Financial Corp, Dimensional Fund Advisors LP, Prudential Financial Inc., Municipal Employees Retirement System of Michigan, Hillsdale Investment Management Inc., Schwab Charles Investment Management Inc., Macquarie Group Ltd. and Alps Advisors Inc.. Company insiders that have bought PDL BioPharma stock in the last two years include Peter S Garcia and Steffen Pietzke. View Insider Buying and Selling for PDL BioPharma.

How do I buy PDL BioPharma stock?

Shares of PDL BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDL BioPharma stock can currently be purchased for approximately $2.84.

How big of a company is PDL BioPharma?

PDL BioPharma has a market capitalization of $439.87 million and generates $244.3 million in revenue each year. The biotechnology company earns $63.6 million in net income (profit) each year or $0.50 on an earnings per share basis. PDL BioPharma employs 11 workers across the globe.

How can I contact PDL BioPharma?

PDL BioPharma's mailing address is 932 Southwood Blvd, INCLINE VILLAGE, NV 89451, United States. The biotechnology company can be reached via phone at +1-775-8328500 or via email at [email protected]


MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  216
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for PDL BioPharma (NASDAQ:PDLI)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.50 (23.24% upside)

Consensus Price Target History for PDL BioPharma (NASDAQ:PDLI)

Price Target History for PDL BioPharma (NASDAQ:PDLI)

Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017Cowen and CompanyReiterated RatingHold$3.00N/AView Rating Details
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$4.00MediumView Rating Details
2/23/2016Royal Bank Of CanadaLower Price TargetSector Perform$5.00 -> $4.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for PDL BioPharma (NASDAQ:PDLI)

Earnings by Quarter for PDL BioPharma (NASDAQ:PDLI)

Earnings History by Quarter for PDL BioPharma (NASDAQ PDLI)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017$0.13$0.14$61.86 million$62.75 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.09$0.26$56.30 million$143.80 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.05$0.08$45.44 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$50.69 million$53.60 millionViewN/AView Earnings Details
8/4/2016Q216$0.08$0.09$33.46 million$21.00 millionViewN/AView Earnings Details
5/4/2016Q116$0.50$0.52$142.05 million$103.10 millionViewN/AView Earnings Details
2/22/2016Q415$0.54$0.61$149.20 million$178.10 millionViewListenView Earnings Details
11/4/2015Q315$0.61$0.42$164.80 million$124.60 millionViewN/AView Earnings Details
8/5/2015Q215$0.52$0.47$137.75 million$138.10 millionViewN/AView Earnings Details
5/6/2015Q115$0.52$0.50$140.80 million$149.71 millionViewN/AView Earnings Details
2/23/2015Q414$0.57$0.32$158.15 million$117.10 millionViewListenView Earnings Details
11/10/2014Q314$0.56$0.61$165.10 million$164.60 millionViewN/AView Earnings Details
8/18/2014Q214$0.46$0.52$134.07 million$162.80 millionViewListenView Earnings Details
5/12/2014Q114$0.45$0.44$130.93 million$139.70 millionViewN/AView Earnings Details
3/3/2014Q413$0.43$0.39$115.22 million$110.10 millionViewN/AView Earnings Details
11/6/2013Q313$0.37$0.36$97.09 million$97.30 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.54$0.62$138.20 million$143.60 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.35$0.36$91.69 million$91.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012$0.31$0.34$86.08 million$86.10 millionViewN/AView Earnings Details
11/5/2012Q312$0.33$0.32$85.03 million$85.20 millionViewN/AView Earnings Details
8/2/2012$0.44$0.52ViewN/AView Earnings Details
5/3/2012$0.27$0.29ViewN/AView Earnings Details
2/23/2012$0.28$0.24ViewN/AView Earnings Details
11/9/2011$0.27$0.28ViewN/AView Earnings Details
7/27/2011$0.39$0.39ViewN/AView Earnings Details
4/27/2011$0.24$0.25ViewN/AView Earnings Details
2/28/2011$0.21$0.20ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for PDL BioPharma (NASDAQ:PDLI)
Current Year EPS Consensus Estimate: $0.67 EPS
Next Year EPS Consensus Estimate: $0.5 EPS

Dividends

Dividend History by Quarter for PDL BioPharma (NASDAQ PDLI)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2016quarterly$0.056.25%6/2/20166/6/20166/13/2016
2/1/2016quarterly$0.057.27%3/2/20163/4/20163/11/2016
2/2/2015quarterly$0.158.22%6/1/20166/5/20166/12/2016
1/30/2015quarterly$0.158.23%6/3/20156/5/20156/12/2015
1/30/2015quarterly$0.158.23%3/3/20153/5/20153/12/2015
1/30/2015quarterly$0.158.23%12/2/201512/4/201512/11/2015
1/30/2015quarterly$0.158.23%9/2/20159/4/20159/11/2015
1/31/2014quarterly$0.156.59%9/3/20149/5/20149/12/2014
1/31/2014quarterly$0.156.59%3/3/20143/5/20143/12/2014
1/31/2014quarterly$0.156.59%12/3/201412/5/201412/12/2014
1/31/2014quarterly$0.156.59%6/3/20146/5/20146/12/2014
1/31/2013quarterly$0.158.72%12/3/201312/5/201312/12/2013
1/31/2013quarterly$0.158.72%6/3/20136/5/20136/12/2013
1/31/2013quarterly$0.158.72%9/3/20139/5/20139/12/2013
1/30/2013quarterly$0.158.72%3/1/20133/5/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for PDL BioPharma (NASDAQ PDLI)

Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 83.38%
Insider Trades by Quarter for PDL BioPharma (NASDAQ:PDLI)
Insider Trades by Quarter for PDL BioPharma (NASDAQ:PDLI)

Insider Trades by Quarter for PDL BioPharma (NASDAQ PDLI)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/24/2017Peter S GarciaVPBuy25,000$1.98$49,500.00View SEC Filing  
8/9/2016Peter S GarciaVPBuy10,000$3.00$30,000.00View SEC Filing  
12/15/2015Peter S. GarciaCFOBuy5,000$3.64$18,200.00View SEC Filing  
12/14/2015Peter S. GarciaCFOBuy10,000$3.42$34,200.00View SEC Filing  
12/7/2015Steffen PietzkeCAOBuy20,590$3.64$74,947.60View SEC Filing  
8/14/2015Peter S GarciaCFOBuy20,000$5.83$116,600.00View SEC Filing  
11/26/2014Harold E SelickDirectorBuy6,000$8.08$48,480.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for PDL BioPharma (NASDAQ:PDLI)

Latest Headlines for PDL BioPharma (NASDAQ PDLI)

Source:
DateHeadline
Noden Pharma Announces FDA Approval of Tekturna®(aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and OlderNoden Pharma Announces FDA Approval of Tekturna®(aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
finance.yahoo.com - November 18 at 10:48 AM
PDL BioPharma, Inc. (PDLI) Given Average Recommendation of "Buy" by AnalystsPDL BioPharma, Inc. (PDLI) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 13 at 12:34 PM
PDL BioPharma to Present at Two Upcoming Investor ConferencesPDL BioPharma to Present at Two Upcoming Investor Conferences
finance.yahoo.com - November 9 at 11:13 AM
Factors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell International, Nektar, PDL Biopharma, and Innoviva – New Research Emphasizes Economic GrowthFactors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell International, Nektar, PDL Biopharma, and Innoviva – New Research Emphasizes Economic Growth
finance.yahoo.com - November 9 at 11:13 AM
EARNINGS SUMMARY: Details of PDL BioPharma Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of PDL BioPharma Inc. Q3 Earnings Report
www.rttnews.com - November 4 at 4:30 PM
PDL BioPharmas (PDLI) CEO John McLaughlin on Q3 2017 Results - Earnings Call TranscriptPDL BioPharma's (PDLI) CEO John McLaughlin on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 4 at 4:30 PM
PDL BioPharma, Inc. to Host Earnings CallPDL BioPharma, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 4:30 PM
PDL BioPharma Announces Third Quarter 2017 Financial ResultsPDL BioPharma Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 4 at 4:30 PM
PDL BioPharma posts 3Q profitPDL BioPharma posts 3Q profit
finance.yahoo.com - November 4 at 4:30 PM
Edited Transcript of PDLI earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of PDLI earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 4:30 PM
PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y - NasdaqPDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y - Nasdaq
www.nasdaq.com - November 4 at 8:43 AM
PDL BioPharma, Inc. (PDLI) Posts Quarterly  Earnings Results, Beats Expectations By $0.01 EPSPDL BioPharma, Inc. (PDLI) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 3 at 6:24 PM
Why Neos Therapeutics Is Holding Out Against PDL BioPharma - 24/7 Wall St.Why Neos Therapeutics Is Holding Out Against PDL BioPharma - 24/7 Wall St.
247wallst.com - October 31 at 7:45 AM
PDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : October 27, 2017PDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : October 27, 2017
finance.yahoo.com - October 28 at 12:43 PM
PDL BioPharma makes unsolicited bid to buy Neos Therapeutics for a 40% premium - MarketWatchPDL BioPharma makes unsolicited bid to buy Neos Therapeutics for a 40% premium - MarketWatch
www.marketwatch.com - October 27 at 9:28 AM
PDL BioPharma, Inc. (PDLI) Set to Announce Earnings on WednesdayPDL BioPharma, Inc. (PDLI) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 8:02 AM
ETFs with exposure to PDL BioPharma, Inc. : October 20, 2017ETFs with exposure to PDL BioPharma, Inc. : October 20, 2017
finance.yahoo.com - October 21 at 8:05 AM
PDL BioPharma, Inc. (PDLI) Expected to Announce Earnings of $0.13 Per SharePDL BioPharma, Inc. (PDLI) Expected to Announce Earnings of $0.13 Per Share
www.americanbankingnews.com - October 12 at 10:30 PM
Amgen Label Expansion Application for Prolia Accepted by FDA - NasdaqAmgen Label Expansion Application for Prolia Accepted by FDA - Nasdaq
www.nasdaq.com - October 11 at 6:30 AM
ETFs with exposure to PDL BioPharma, Inc. : October 9, 2017ETFs with exposure to PDL BioPharma, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 11:49 PM
PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017
finance.yahoo.com - October 3 at 10:31 AM
ETFs with exposure to PDL BioPharma, Inc. : September 28, 2017ETFs with exposure to PDL BioPharma, Inc. : September 28, 2017
finance.yahoo.com - October 3 at 10:31 AM
Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% HigherSeattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher
finance.yahoo.com - October 3 at 10:31 AM
PDL BioPharma, Inc. (PDLI) Sees Significant Growth in Short InterestPDL BioPharma, Inc. (PDLI) Sees Significant Growth in Short Interest
www.americanbankingnews.com - September 28 at 3:18 AM
PDL BioPharma (PDLI) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowPDL BioPharma (PDLI) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 6:08 PM
PDL BioPharma (PDLI) Reports $25M Share Buyback ProgramPDL BioPharma (PDLI) Reports $25M Share Buyback Program
www.streetinsider.com - September 25 at 5:01 PM
Stock Buyback Plan Declared by PDL BioPharma (PDLI) Board of Directors Stock Buyback Plan Declared by PDL BioPharma (PDLI) Board of Directors
www.americanbankingnews.com - September 25 at 11:24 AM
PDL BioPharma Announces New $25 Million Share Repurchase ProgramPDL BioPharma Announces New $25 Million Share Repurchase Program
finance.yahoo.com - September 25 at 10:53 AM
PDL BioPharma, Inc. (PDLI) Given Average Recommendation of "Hold" by BrokeragesPDL BioPharma, Inc. (PDLI) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 24 at 1:16 PM
Head-To-Head Comparison: PDL BioPharma (PDLI) versus The CompetitionHead-To-Head Comparison: PDL BioPharma (PDLI) versus The Competition
www.americanbankingnews.com - September 23 at 10:22 AM
Should Value Investors Consider PDL BioPharma, Inc. (PDLI) Stock? - NasdaqShould Value Investors Consider PDL BioPharma, Inc. (PDLI) Stock? - Nasdaq
www.nasdaq.com - September 22 at 8:40 AM
Pluristems Ischemia Candidate Gets Fast Track DesignationPluristem's Ischemia Candidate Gets Fast Track Designation
finance.yahoo.com - September 20 at 7:34 AM
PDL BioPharma Updates Presentation Time for Cantor Fitzgerald ConferencePDL BioPharma Updates Presentation Time for Cantor Fitzgerald Conference
finance.yahoo.com - September 20 at 7:34 AM
Financial Contrast: PDL BioPharma (PDLI) vs. Charles River Laboratories International (CRL)Financial Contrast: PDL BioPharma (PDLI) vs. Charles River Laboratories International (CRL)
www.americanbankingnews.com - September 19 at 8:52 AM
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
finance.yahoo.com - September 15 at 7:29 AM
PDL BioPharma, Inc. (PDLI) Sees Large Increase in Short InterestPDL BioPharma, Inc. (PDLI) Sees Large Increase in Short Interest
www.americanbankingnews.com - September 14 at 1:46 AM
PDL BioPharma (PDLI) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowPDL BioPharma (PDLI) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 7:40 AM
PDL BioPharma Appoints Dominique Monnet as PresidentPDL BioPharma Appoints Dominique Monnet as President
finance.yahoo.com - September 12 at 8:28 AM
PDL BioPharma: Q2 Update - Seeking AlphaPDL BioPharma: Q2 Update - Seeking Alpha
seekingalpha.com - September 7 at 7:32 AM
$0.13 Earnings Per Share Expected for PDL BioPharma, Inc. (PDLI) This Quarter$0.13 Earnings Per Share Expected for PDL BioPharma, Inc. (PDLI) This Quarter
www.americanbankingnews.com - September 5 at 12:14 PM
PDL BioPharma, Inc. (PDLI) Receives Average Rating of "Buy" from AnalystsPDL BioPharma, Inc. (PDLI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 30 at 1:00 PM
Why PDL BioPharma (PDLI) Could Be Positioned for a Surge - NasdaqWhy PDL BioPharma (PDLI) Could Be Positioned for a Surge - Nasdaq
www.nasdaq.com - August 29 at 6:35 AM
Why PDL BioPharma (PDLI) Could Be Positioned for a SurgeWhy PDL BioPharma (PDLI) Could Be Positioned for a Surge
finance.yahoo.com - August 29 at 6:35 AM
5 Bargain Breakout Stocks Offering Stunning Returns5 Bargain Breakout Stocks Offering Stunning Returns
finance.yahoo.com - August 24 at 10:54 AM
3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock - Nasdaq3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock - Nasdaq
www.nasdaq.com - August 19 at 6:26 AM
3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock - Nasdaq3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock - Nasdaq
www.nasdaq.com - August 19 at 6:26 AM
3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock
finance.yahoo.com - August 19 at 6:25 AM
3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock
finance.yahoo.com - August 19 at 6:25 AM
$0.08 EPS Expected for PDL BioPharma, Inc. (PDLI) This Quarter$0.08 EPS Expected for PDL BioPharma, Inc. (PDLI) This Quarter
www.americanbankingnews.com - August 18 at 12:20 AM
ETFs with exposure to PDL BioPharma, Inc. : August 14, 2017ETFs with exposure to PDL BioPharma, Inc. : August 14, 2017
finance.yahoo.com - August 15 at 6:09 AM

Social Media

Financials

Chart

PDL BioPharma (NASDAQ PDLI) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.